Department of Nuclear Medicine, Yunnan Tumor Hospital, The Third Affiliated Hospital of Kunming Medical University, Kunming, China.
Department of SICU, The Second Affiliated Hospital of Kunming Medical University, Kunming, China.
Cell Transplant. 2023 Jan-Dec;32:9636897231164251. doi: 10.1177/09636897231164251.
Kidney disease (KD) is a life-threatening disease characterized by high morbidity and mortality in clinical settings, which can be caused by many reasons, and the incidence increases with age. However, supportive therapy and kidney transplantation still have limitations in alleviating KD progression. Recently, mesenchymal stem cells (MSCs) have shown great potential in repairing injury through their multidirectional differentiation and self-renewal ability. Of note, MSCs serve as a safe and effective therapeutic strategy for treating KD in preclinical and clinical trials. Functionally, MSCs ameliorate KD progression by regulating the immune response, renal tubular cell apoptosis, tubular epithelial-mesenchymal transition, oxidative stress, angiogenesis, and so on. In addition, MSCs exhibit remarkable efficacy in both acute kidney injury (AKI) and chronic kidney disease (CKD) through paracrine mechanisms. In this review, we outline the biological characteristics of MSCs, discuss the efficacy and mechanisms of MSCs-based therapy for KD, summarize the completed and ongoing clinical trials, as well as analyze limitations and new strategies, aiming to provide new ideas and approaches for the preclinical experiments and clinical trials of MSCs transplantation for KD.
肾脏疾病(KD)是一种在临床环境中具有高发病率和死亡率的危及生命的疾病,可由多种原因引起,并且发病率随着年龄的增长而增加。然而,支持性治疗和肾移植在缓解 KD 进展方面仍然存在局限性。最近,间充质干细胞(MSCs)通过其多向分化和自我更新能力在修复损伤方面显示出巨大的潜力。值得注意的是,MSCs 作为一种安全有效的治疗 KD 的策略,在临床前和临床试验中得到了验证。功能上,MSCs 通过调节免疫反应、肾小管细胞凋亡、肾小管上皮-间充质转化、氧化应激、血管生成等,改善 KD 进展。此外,MSCs 通过旁分泌机制在急性肾损伤(AKI)和慢性肾脏病(CKD)中均显示出显著疗效。在这篇综述中,我们概述了 MSCs 的生物学特性,讨论了基于 MSCs 的治疗 KD 的疗效和机制,总结了已完成和正在进行的临床试验,并分析了局限性和新策略,旨在为 MSCs 移植治疗 KD 的临床前实验和临床试验提供新的思路和方法。